ADC Therapeutics SA joins Russell 2000 and 3000 Indexes on July 1, reflecting progress in hematology and solid tumor portfolios.

ADC Therapeutics SA to join Russell 2000® and broad-market Russell 3000® Indexes at end of annual reconstitution. This inclusion, effective July 1, validates the company's capital allocation and progress towards upcoming milestones in hematology and solid tumor portfolios. ADC Therapeutics, a NYSE-listed company, will become part of the US all-cap Russell 3000® Index for one year.